BMS-378806 是一种有效的 HIV-1 抑制剂，干扰 CD4-gp120 相互作用。BMS-378806选择性抑制 HIV-1 gp120 结合到 CD4 受体，EC50 为 0.85-26.5 nM。
In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案，配制前请先配制澄清的储备液，再依次添加助溶剂 (为保证实验结果的可靠性，体内实验的工作 液，建议您现用现配，当天使用；澄清的储备液可以根据储存条件，适当保存；以下溶剂前的百分比是指该溶剂在您配制终溶液中的体积占比)：
1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (6.15 mM); Clear solution.
2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.15 mM); Clear solution 3. 请依序添加每种溶剂： 10% DMSO 90% corn oil Solubility: ≥ 2.5 mg/mL (6.15 mM); Clear solution
参考文献：
[1].Wang
T, et al. Discovery of 4-benzoyl-1-[(4-methoxy-1H-
pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine
(BMS-378806): a novel HIV-1 attachment inhibitor that interferes with
CD4-gp120 interactions. J Med Chem. 2003 Sep 25;46(20):4236-9.
[2].Ho
HT, et al. Envelope conformational changes induced by human
immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding
and downstream entry events. J Virol. 2006 Apr;80(8):4017-25.
[3].Guo
Q, et al. Biochemical and genetic characterizations of a novel human
immunodeficiency virus type 1 inhibitor that blocks gp120-CD4
interactions. J Virol. 2003 Oct;77(19):10528-36.
